“…Patients underwent in vitro fertilization and embryo transfer (IVF‐ET) with a standardized ovarian‐stimulation protocol as reported previously [31] consisting of GnRH agonist (900 mg/day buserelin acetate, Suprecur; Mochida Pharmaceutical Co. Ltd., Tokyo, Japan) beginning in the mid‐luteal phase, followed by 300 IU follicle stimulating hormone (FSH, Fertinorm P; Serono‐Japan Co. Ltd., Chiba, Japan) on the second and third day, 225 IU FSH on day 4 and 5, and thereafter by 150 IU human menopausal gonadotropins (hMG, HMG‐teizo; Asuka Co. Ltd., Tokyo, Japan). When at least three follicles reached 18 mm or more in diameter by ultrasonography 10,000 IU human chorionic gonadotropin (Gonatropin; Asuka Pharmaceutical Co., Ltd., Tokyo, Japan) was administered and an ultrasound‐guided trans‐vaginal oocyte retrieval was performed 34 hr later.…”